Who are the top shareholders of the Family Care?

The top shareholders of Family Care are primarily individual investors, holding 75.59% of the company. Gautam Mohan Deshpande is the largest promoter with 11.44%, while the highest public shareholder is Bala Venkata Reddy Ummalareddy at 1.02%, with no holdings from mutual funds or foreign institutional investors.

The top shareholders of Family Care primarily consist of individual investors, who hold a significant 75.59% of the company. The majority of the shareholding is non-institutional, with Gautam Mohan Deshpande being the promoter with the highest holding at 11.44%. The highest public shareholder is Bala Venkata Reddy Ummalareddy, who holds 1.02%. Additionally, there are no holdings reported from mutual funds or foreign institutional investors.

how big is Family Care?

As of Jun 06, Family Care Hospitals Ltd has a market capitalization of 24.00 Cr, with net sales of 7.90 Cr and a net profit of -44.15 Cr over the latest four quarters. The standalone balance sheet shows shareholder's funds of 58.37 Cr and total assets of 69.96 Cr.

As of Jun 06, Family Care Hospitals Ltd has a market capitalization of 24.00 Cr, which classifies it as a Micro Cap company.<BR><BR>As of Jun 06, the company reported a sum of Net Sales for the latest 4 quarters amounting to 7.90 Cr and a sum of Net Profit of -44.15 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Standalone balance sheet shows Shareholder's Funds of 58.37 Cr and Total Assets of 69.96 Cr.

Has Family Care declared dividend?

No Dividend History Available

Who are the peers of the Family Care?

Family Care's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Gian Lifecare, Vanta Bioscience, Clinitech Lab, and Dhanvantri Jeev. In terms of management risk, Family Care is rated average, with Poly Medicure showing the highest 1-year return at 24.17% and Family Care at -38.69%.

Peers: The peers of Family Care are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Gian Lifecare, Vanta Bioscience, Clinitech Lab, and Dhanvantri Jeev.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Clinitech Lab. Average management risk is noted for Family Care, and Below Average management risk is seen at Gian Lifecare and Dhanvantri Jeev. Growth ratings are Good for Family Care, Average for Poly Medicure, Indegene, and Gian Lifecare, and Below Average for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Dhanvantri Jeev. Excellent capital structure is attributed to Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Family Care, while Good capital structure is found at Gian Lifecare and Clinitech Lab, and Below Average capital structure is noted for Dhanvantri Jeev.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.17%, while the lowest is Vanta Bioscience at -54.78%. Family Care's own 1-year return is -38.69%, which is significantly lower than Poly Medicure's. Additionally, the six-month returns for Syngene Intl., Family Care, Gian Lifecare, Vanta Bioscience, Clinitech Lab, and Dhanvantri Jeev. are all negative.

What is the technical trend for Family Care?

As of May 30, 2025, Family Care's technical trend has shifted to a bearish stance with weak strength, supported by bearish daily moving averages and mixed signals from MACD and KST, while significantly underperforming against the Sensex.

As of 30 May 2025, the technical trend for Family Care has changed from mildly bearish to bearish. The current stance is bearish with weak strength, primarily driven by the daily moving averages indicating a bearish trend and both weekly and monthly Bollinger Bands confirming a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, indicating mixed signals. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall bearish sentiment. The stock has underperformed significantly compared to the Sensex over multiple time frames, which reinforces the bearish outlook.

Who are in the management team of Family Care?

As of March 2022, the management team of Family Care includes Rajnish Kumar Pandey (Independent Director), Pandoo Neig (Managing Director), Dhananjay Parikh (Non-Executive & Independent Director), and Lucy Massey (Additional Non-Executive Director). They are responsible for the company's governance and strategic direction.

As of March 2022, the management team of Family Care includes the following members:<BR><BR>1. Rajnish Kumar Pandey - Independent Director<BR>2. Pandoo Neig - Managing Director<BR>3. Dhananjay Parikh - Non-Executive & Independent Director<BR>4. Lucy Massey - Additional Non-Executive Director<BR><BR>These individuals play key roles in the governance and strategic direction of the company.

What does Family Care do?

Family Care Hospitals Ltd is a micro-cap healthcare services company, previously known as Pharma Offset Limited, with a market cap of INR 24 Cr, reporting net sales of 0 Cr and a net profit of 10 Cr for the quarter ending March 2025. Key financial metrics include a P/E ratio of 1.00 and a return on equity of 226.54%.

Overview:<BR>Family Care Hospitals Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Pharma Offset Limited. It underwent several name changes, becoming Pharma Com (India) Limited in June 2000 and later Count N Denier (India) Limited in March 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 10 Cr (Quarterly Results - Mar 2025) <BR>Market-cap: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 1.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 226.54% <BR>Price to Book: 1.76<BR><BR>Contact Details:<BR>Address: Plot No A-357 Road No 26, Wagle Industrial Estate MIDC Thane (West) Maharashtra : 400604 <BR>Tel: 91-22-25833205 <BR>Email: csscandent@gmail.com <BR>Website: http://www.scandent.in

When is the next results date for Family Care?

The next results date for Family Care is 28 October 2025.

The next results date for Family Care is scheduled for 28 October 2025.

Should I buy, sell or hold Family Care?

Are Family Care latest results good or bad?

Family Care Hospitals' latest results are concerning, showing a net loss of ₹4.61 crores in Q2 FY26, a 558.57% decline from the previous quarter, and revenue dropping 98.20% year-on-year to just ₹0.07 crores. These figures indicate severe operational challenges and raise significant concerns about the company's viability.

The latest results for Family Care Hospitals are quite concerning and indicate a severe operational crisis. In Q2 FY26, the company reported a net loss of ₹4.61 crores, which is a staggering 558.57% decline compared to the previous quarter. Revenue has plummeted to just ₹0.07 crores, reflecting a 98.20% year-on-year drop from ₹3.88 crores in Q2 FY25. This dramatic decline in revenue suggests that the company has virtually ceased meaningful operations.<BR><BR>The operating margin is alarmingly negative at -6,271.43%, indicating that the core business is generating massive losses. Furthermore, the profit after tax (PAT) margin is also deeply negative at -6,585.71%, which signifies that the company is losing more than ₹65 for every rupee of revenue.<BR><BR>Overall, these results paint a picture of a company in distress, facing significant challenges to its business model and sustainability. The financial metrics suggest a critical need for immediate intervention to address these issues, as the current trajectory raises serious questions about the company's viability moving forward.

How has been the historical performance of Family Care?

Family Care's historical performance has been volatile, with net sales peaking at 47.30 Cr in March 2023 but plummeting to 7.90 Cr by March 2025, alongside significant declines in operating income and total assets. Despite a rise in operating profit due to negative expenditures, profit before tax fell sharply to -44.47 Cr in March 2025.

Answer:<BR>The historical performance of Family Care has shown significant fluctuations over the years, particularly in net sales and profitability. <BR><BR>Breakdown:<BR>Family Care's net sales peaked at 47.30 Cr in March 2023 but dramatically fell to 7.90 Cr by March 2025. This decline in sales is reflected in the total operating income, which also decreased from 40.01 Cr in March 2024 to 7.90 Cr in March 2025. The company's total expenditure, which was 33.26 Cr in March 2024, turned negative at -20.51 Cr in March 2025, indicating a drastic change in operational efficiency. Operating profit, which had been positive in previous years, saw a significant rise to 31.56 Cr in March 2025, largely due to the negative expenditure. However, the profit before tax plummeted to -44.47 Cr in March 2025, following an exceptional item of -74.62 Cr. Consequently, profit after tax also fell to -44.15 Cr. The company's total assets decreased from 69.96 Cr in March 2024 to 46.09 Cr in March 2025, while total liabilities also dropped from 69.96 Cr to 46.09 Cr in the same period. Cash flow from operating activities turned negative at -17.00 Cr in March 2025, contrasting with the previous year's positive cash flow. Overall, Family Care's financial performance has been marked by volatility, particularly in sales and profitability metrics.

Is Family Care overvalued or undervalued?

As of October 29, 2025, Family Care is considered overvalued and risky due to severe profitability issues, reflected in a negative PE ratio of -3.62 and a year-to-date return of -35.44%, significantly underperforming compared to its peers like Max Healthcare and Apollo Hospitals.

As of 29 October 2025, Family Care's valuation grade has moved from fair to risky, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued, with a PE ratio of -3.62, an EV to EBITDA of -3.48, and a ROE of -47.73%. These figures suggest severe profitability issues, particularly when compared to its peers. For instance, Max Healthcare has a PE ratio of 96.03 and an EV to EBITDA of 59.47, while Apollo Hospitals shows a PE of 71.83 and an EV to EBITDA of 36.92, both indicating a stark contrast in financial health.<BR><BR>The company’s performance has been notably poor, with a year-to-date return of -35.44%, significantly underperforming the Sensex, which has returned 8.78% in the same period. Given the substantial negative ratios and the company's poor performance relative to its peers, Family Care is clearly overvalued in the current market context.

Which are the latest news on Family Care?

Why is Family Care falling/rising?

As of 19-Dec, Family Care Hospitals Ltd's stock price is rising to 3.71, reflecting a 3.34% increase. This rise is driven by improved investor sentiment, increased participation, and the stock outperforming its sector despite trading below moving averages.

As of 19-Dec, Family Care Hospitals Ltd's stock price is rising, currently at 3.71, reflecting a change of 0.12 or 3.34% increase. This rise can be attributed to several factors. Notably, the stock has outperformed its sector by 1.52% today, indicating a positive performance relative to its peers. Additionally, there has been a trend reversal as the stock has gained after three consecutive days of decline, suggesting a potential shift in investor sentiment.<BR><BR>Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 32.33% against the five-day average, which indicates growing interest in the stock. Despite the stock trading lower than its moving averages across various time frames, the overall positive movement in the Hospital & Healthcare Services sector, which gained by 2.03%, may also be contributing to the stock's rise.